Michael Phelps
Family Medicine · Tigard, ORNPI 1699060780
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,000 and has fallen 79.0% since, to $210 in 2025. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$468
- AbbVie$273
- Boehringer Ingelheim$270
- Novo Nordisk$264
- AstraZeneca$213
- GSK$188
- plus $2K from 26 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lucid Diagnostics Inc.$500
What the payments were for
- Food & beverage$3,266100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 23 | $468 |
| AbbVie | 17 | $273 |
| Boehringer Ingelheim | 11 | $270 |
| Novo Nordisk | 13 | $264 |
| AstraZeneca | 13 | $213 |
| GSK | 10 | $188 |
| Pfizer | 10 | $176 |
| Merck | 14 | $172 |
| Amgen(2 entities) | 10 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $106 |
| Eisai Inc. | 5 | $97 |
| Gilead | 4 | $77 |
| Exact Sciences | 3 | $76 |
| Inspire Medical Systems, Inc. | 2 | $75 |
| Lilly USA, LLC | 4 | $68 |
| Lucid Diagnostics Inc. | 5 | $58 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| Shire North American Group Inc | 3 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Boston Scientific | 1 | $43 |
| Sanofi Pasteur Inc. | 2 | $42 |
| Medtronic(2 entities) | 2 | $35 |
| Lundbeck LLC | 1 | $31 |
| Hologic Sales And Service, LLC | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Vertex | 1 | $26 |
| Novartis | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Si-bone, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$3,266 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 25 | $18,258 |
| EliquisApixaban | 14 | $9,999 |
| Atorvastatin Calcium | 46 | $468 |
| Gabapentin | 16 | $373 |
| Metoprolol Succinate | 11 | $217 |
| Losartan Potassium | 24 | $184 |
| Metformin Hcl | 22 | $122 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $115 |
| Lisinopril | 12 | $83 |
| Trazodone Hcl | 11 | $78 |
| Levothyroxine Sodium | 14 | $73 |
| Rosuvastatin Calcium | 11 | $72 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $270 | $18,25825 claims |
| PfizerEliquis | $176 | $9,99914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Tigard
- Standley AdamekTigard$4K
- Andrea TremaineTigard$3K
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.